The DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis
Open accessAbstract
Pirfenidone is one of two approved therapies for the treatment of idiopathic pulmonary fibrosis (IPF). Randomised controlled clinical trials and subsequent post hoc analyses have demonstrated that pirfenidone reduces lung function decline, decreases mortality and improves progression-free survival. Long-term extension trials, registries and real-world studies have also shown similar treatment effects with pirfenidone. However, for patients with IPF to obtain the maximum benefits of pirfenidone treatment, the potential adverse events (AEs) associated with pirfenidone need to be managed. This review highlights the well-known and established safety profile of pirfenidone based on randomised controlled clinical trials and real-world data. Key strategies for preventing and managing the most common pirfenidone-related AEs are described, with the goal of maximising adherence to pirfenidone with minimal AEs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A phase 1 trial demonstrated that deupirfenidone reduced GI AEs by 50% [36].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationvan den Hoogen, F., Khanna, D., Fransen, J., Johnson, S. R., Baron, M., Tyndall, A., Matucci‐Cerinic, M., Naden, R. P., Medsger, T. A., Carreira, P. E., et al. (2013) · Arthritis & Rheumatism · doi:10.1002/art.38098 · Cited by 3,409
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Self-citationRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
Ley, B., Collard, H. R., & King, T. E. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201006-0894ci · Cited by 1,765
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
Hutchinson, J., Fogarty, A., Hubbard, R., & McKeever, T. (2015) · European Respiratory Journal · doi:10.1183/09031936.00185114 · Cited by 913
Raghu, G., Chen, S.-Y., Yeh, W.-S., Maroni, B., Li, Q., Lee, Y.-C., & Collard, H. R. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70101-8 · Cited by 716
Incidence, Prevalence, and Clinical Course of Idiopathic Pulmonary Fibrosis
Fernández Pérez, E. R., Daniels, C. E., St. Sauver, J., Hartman, T. E., Bartholmai, B. J., Yi, E. S., Ryu, J. H., & Schroeder, D. R. (2010) · Chest · doi:10.1378/chest.09-1002 · Cited by 509
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., du Bois, R. M., Fagan, E. A., Fishman, R. S., Glaspole, I., Glassberg, M. K., Lancaster, L., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00026-2015 · Cited by 468
Self-citation
Research works printed but not linked: 4
- Lancaster, 2016, Safety of pirfenidone in patients with idiopathic pulmonary fibrosis in a US expanded access program, Am J Respir Crit Care Med, 193, A2695
- Mason, 2017, Time-to-event analysis of common adverse events with pirfenidone in patients with IPF – a pooled analysis of three phase III clinical trials, Am J Respir Crit Care Med, 195, A6798
- Lancaster, 2017, Pirfenidone in patients aged 80 years and older with idiopathic pulmonary fibrosis (IPF): safety findings from pooled trial databases, Am J Respir Crit Care Med, 195, A5385
- Glassberg, 2016, Cardiovascular events in phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis (IPF), Am J Respir Crit Care Med, 193, A4980
Cited by
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
Maher, T. M., & Strek, M. E. (2019) · Respiratory Research · doi:10.1186/s12931-019-1161-4 · Cited by 265
“Pirfenidone is more commonly associated with nausea and decreased appetite than with diarrhea [54, 55] and is recommended to be taken during or after a meal to minimize gastrointestinal issues.”
BackgroundDiverse Role of TGF-β in Kidney Disease
Gu, Y.-Y., Liu, X.-S., Huang, X.-R., Yu, X.-Q., & Lan, H.-Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00123 · Cited by 257
Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Sweeney, M., Corden, B., & Cook, S. A. (2020) · EMBO Molecular Medicine · doi:10.15252/emmm.201910865 · Cited by 195
“Long-term pirfenidone treatment requires surveillance for hepatotoxicity; however, it is generally well tolerated and tranilast has limited toxicities (Lancaster et al, 2017).”
BackgroundCurrent and Future Treatment Landscape for Idiopathic Pulmonary Fibrosis
Bonella, F., Spagnolo, P., & Ryerson, C. (2023) · Drugs · doi:10.1007/s40265-023-01950-0 · Cited by 182
“Dose reduction, dietary modifications, and skin protection are widely used strategies to manage adverse effects [61, 62].”
Background
Metadata
- Authors
- Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U.
- Affiliations
- Vanderbilt University Medical Center (US)
- Beth Israel Deaconess Medical Center (US)
- University of Turin (IT)
- Inova Fairfax Hospital (US)
- Erasmus MC (NL)
- Genentech (US)
- F. Hoffmann-La Roche AG (CH)
- Ruhrlandklinik (DE)
- Corresponding author
- Lancaster, Lisa H.
- Venue
- European Respiratory Review
- Publisher
- European Respiratory Society (ERS)
- Published
- 2017-12-06
- Volume
- 26
- Issue
- 146
- Pages
- 170057
- ISSN
- 0905-9180 (ISSN-L)
- 1600-0617
- PMC
- PMC9488585
- OpenAlex
- W2774138788
- Cited by
- 295
- References
- 52
- Citations by year
- 2026: 36 · 2025: 45 · 2024: 36 · 2023: 50 · 2022: 35 · 2021: 29 · 2020: 38 · 2019: 17 · 2018: 9
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- European Respiratory Review (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Funders
- GlaxoSmithKline
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- F. Hoffmann-La Roche
- Veracyte
- National Institutes of Health
- Genentech
- National Heart, Lung, and Blood Institute
- UCB Celltech
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- pirfenidone, idiopathic pulmonary fibrosis, drug safety, adverse events, adverse event management, medication adherence, lung function decline, real-world data
- MeSH terms
- Anti-Inflammatory Agents, Non-Steroidal, Humans, Lung, Pyridones, Risk Factors, Time Factors, Treatment Outcome, Disease-Free Survival, Recovery of Function, Idiopathic Pulmonary Fibrosis, Medication Adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. https://app.cochat.ai/papers/10.1183/16000617.0057-2017
- The paper
- Lancaster, L. H., de Andrade, J. A., Zibrak, J. D., Padilla, M. L., Albera, C., Nathan, S. D., Wijsenbeek, M. S., Stauffer, J. L., Kirchgaessler, K.-U., & Costabel, U. (2017). Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European Respiratory Review. https://doi.org/10.1183/16000617.0057-2017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.